Edesa Biotech, Inc.: 5%+ holders

Edesa Biotech, Inc. has 15 Schedule 13D or 13G filings on record since 2026-02-13. 7 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Velan Capital Investment Management LP

Item 4 is hereby amended to add the following: On August 21, 2026, in an underwritten public offering (the "Offering"), Velan Master purchased 445,100 Shares and certain warrants (the "New Warrants") exercisable into 445,100 Shares and Velan Horizon purchased 9,445 Shares and New Warrants exercisable into 9,445 Shares. Velan Master and Velan Horizon may not exercise any portion of the New Warrants to the extent that they would beneficially own more than 9.99% of the number of Shares outstanding immediately after giving effect to such exercise. However, upon at least 61 days' prior notice to the Issuer, such Reporting Person may increase or decrease such beneficial ownership limitation, as applicable, but not to any percentage in excess of 9.99% (the "Warrant Ownership Limitation"). Each New Warrant is exercisable for one Share at an exercise price of $7.50 per Share. The New Warrants are exercisable at any time after their original issuance and may be exercised until the date that is the earlier of (i) the 18-month anniversary of the original issuance date and (ii) the 30th day following the date of the Issuer's public announcement of Phase 2 vitiligo topline data for EB06. The exercise price and the number of Shares issuable upon exercise of the New Warrants are subject to appropriate adjustment in the event of certain share dividends, share splits, share combinations or other similar reclassifications affecting the Shares. The foregoing description of the New Warrant is …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-25; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes